Member Info for PM2022

Valid point Andy. A decent amount of outgoings every month is for all the work that is required to outsource to other labs. We would also make some with further contracts we could actually end up making a profit or breaking even but at the same time the projects move forward quicker with less delays.

A Lease removes some of the uncertainty regarding the needs of a placing to buy one and is a positive for shareholders if costs are favourable which I think it will be. Seems really positive and still lots of news to come including 201. All relative to the current SP so we only need one good piece of news at these prices.

How can they sell 201 if the license agreement gives Val % royalties. Not logical and would legally not be allowed unless VAL agreed to it and if they did they would be asking for many millions.

As I said it is not that expensive so they can afford to bring in contracts as time goes on. I have added my estimated lab fee with zero contracts and still we have enough cash for about a year.

RIsk to reward is very favorable if you take a balanced approach.

Porky these are very basic questions and ones Adam has answered 100s of times. They cannot raise enough for a lab at these prices.

A lease for a lab works heavily in our favour. We cover costs with new contracts and it is not that expensive and allows them to work quicker on current projects. If it costs 150-200k a year they can get that revenue with the contract work they do on the side.

201 will get done. Suzy has indicated this again and again. Timing is not in her control and due to patent issues it would take longer with someone else.

Nothing has changed. If any of 301, 401 or 201 comes good we still go towards 50p with one more in SPV. I have done my workings for the amount of cash I think they have and I would say about 1 year from here but that said I think 201 will get done before then and that would allow Cenkos to cash in on the warrants.

Standard dip then buyers come in. I am saying we should still be worth far more than 15p and nothing has changed other than a delay on one project. We still have cash for at least 1 year and 201 will likely get done.

No change still cash for another year. Just an extension to the evaluation but the next one is due in a few weeks. We should still get 2 in SPV just means a slightly longer wait.

She is not allowed to say anything on 201 so that can happen at any point. At 15p it's a hold for me.

Likely RNS signal as one is guaranteed before the deadline if going based on the Zoom which confirmed news before the deadline. Two in SPV would be a new making for this company as we should be no less than 30p just on these two SPVs and with 201 at zero at the moment.

At the conclusion of the evaluation period (December 2022), the Company has an option to license the technology on pre-agreed terms.

Dr Suzy Dilly, CEO of ValiRx commented: "The peptide drug candidate under evaluation in this agreement has been developed for a completely novel cancer target. This cutting-edge technology has potential to enable a first in class drug development programme to be launched in these important therapeutic areas."

Agree. The situation has gotten personal but in reality it does not matter but what does matter is getting the SP up.

We are massively undervalued and in these situations knowledge is power and the more people that understand the company and the potential value on offer the more that will buy at these prices.

Nothing has changed. Still expected and it will still very likely happen soon.

As I always say the smart ones buy at these levels and dumb ones likes you just moan.

Be greedy when others are fearful.

Do just that Lockdown but don't come here and claim to be a holder before that level if we do not get to that price. Easy to speak after a stock moves up or down like you do. A bit childish if you ask me.

That is fine but moving forward, surely not much any downside and almost unlimited upside depending on how long you are looking to invest.

A perfect entry point here imo with lots of news due.

So you got a strong sell on your post. Clearly you want to buy cheaper.

Reality is that news is due on the evaluation and all the hints are positive. 201 deal is not priced and with 2 in SPV that would be huge for any AIM pharma. We should be no less than 30 p with that alone.

The fact they persist with TRX tells me they are confident that the deal will complete but the timeline we cannot be sure about. As long as it gets done hopefully as soon as possible then upside could be to 70-80 p.

Don't be stingy all your life to buy 0.5 or 1 p cheaper which may never happen given news is due. if you want to buy then buy.

It is finally time for the big RNS. Anytime from tomorrow to before Christmas we will get news on this.

Two in SPV should value us at a minimum of 30p and that with the 201 deal priced at zero at the moment. Lots of news is due and we should get some news regarding private investors for our TNBC drug soon. Maybe a GSK investing 2 million for a 10 % stake would be nice.

Under the agreement, the Company will carry out a defined series of preclinical tests on the peptide drug candidate molecule over the next twelve months to validate the technology and determine suitability for commercialisation. This preclinical evaluation, the cost of which will be borne by ValiRx of up to £100,000, will investigate the action of the molecule against Endometrial, Pancreatic and Bile Duct Cancers.

At the conclusion of the evaluation period (December 2022), the Company has an option to license the technology on pre-agreed terms.

Dr Suzy Dilly, CEO of ValiRx commented: "The peptide drug candidate under evaluation in this agreement has been developed for a completely novel cancer target. This cutting-edge technology has potential to enable a first in class drug development programme to be launched in these important therapeutic areas."

Never a better time to get news out. Punish the person who is trying to trade and lower the SP to buy again. He is damaging the company if he keeps buying and selling and it would be a great time to get news out at these levels.

Only a few days left of November and hopefully news on the evaluation and if we are lucky 201 in the coming days.

The difference is that not everyone will make money. When the news drops the 50k seller if it is true will be buying much higher and probably be sitting on losses. At these prices and given the timings before news not worth selling any imo. If 201 comes we could get a gap up to at least 30p and move up fast.

The way I see it if the evaluation is successful we move to 30p. That would be two in SPV. Val tweeted positively regarding pancreatic cancer last week and our next evaluation due in the coming days/weeks is regarding pancreatic cancer.

Patrick has also been tweeting regarding trust vs performance. I think Suzy's plans revolve around getting 201 done first and I think it's a great time to be invested before Christmas. News is due and even if it went down 2p from here I know it would go back up. WIN-WIN. All in my opinion.

With Thanksgiving this week and Christmas coming up and huge upside it is all about now.

I just added another 25000 shares. Now is the time to be in this leading up to Christmas.

Big week in the calendar this week. It's Thanksgiving week in the US. I have seen some positive Tweets recently so I am confident we will get news in the next two weeks possibly regarding both 201 and the drug under evaluation.

Agree very cheap as most long terms have averages above 20p so cheap to buy with not much sellers given the amount of news that is due.

We will get volume and I agree Suzy may attract some new investors from the events she is attending. Only a matter of time before we hit 25-30p before news.

Looks like a big buyer at 18p so the support is very strong here. We should break 20p soon with a few buys.

Nice rise to 20-25p before news is very likely.

Next week is the last full week of November. I don't think news will come the week before Christmas as it is usually quiet. Looking at the calendar I feel we get news next week or the week after.

Still few updates before Christmas. Half year update, News regarding a new drug, Outcome of Hokkaido evaluation and 201 news soon as stated in the presentation.

I would say this is the best time of the year to buy with Christmas coming up given our current SP and potential upside and news that is due. The risk to reward is very good here provided one can be patient.

It will do if 201 news comes out tomorrow.

People know that news will soon come. Early signs and we are looking strong here.